24/7 Market News Snapshot 17 July, 2025 – Cybin Inc. (NYSE:CYBN)

July 17, 2025

DENVER, Colo., 17 July, 2025 (www.247marketnews.com) – (NYSE:CYBN) are discussed in this article.
Cybin Inc. (CYBN) is experiencing notable upward momentum in the market, with shares opening at $7.50 and currently trading at $8.323, reflecting a significant increase of 10.68%. The previous closing price was $7.520, suggesting a robust bullish trend. Current trading volume stands at 631.09K, indicating heightened investor interest. Traders should watch key support levels around $7.50 and potential resistance near the $8.50 mark. The recent activity in share price signals strong market sentiment, although analysts advise vigilance for possible corrections, recommending close observation of volume trends to confirm ongoing bullishness.

In a significant advancement for the company, Cybin has received approval from the UK Medical and Healthcare Products Regulatory Agency (MHRA) to commence the EMBRACE study, part of its Phase 3 multinational PARADIGM program. This pivotal trial aims to investigate CYB003, a proprietary deuterated psilocin analog, as an adjunctive treatment for Major Depressive Disorder (MDD). Doug Drysdale, the CEO of Cybin, hailed this approval as a crucial milestone that underscores the strong foundation of their data and the pressing requirement for innovative therapies in the field of depression treatment.

The EMBRACE study plans to enroll 330 participants suffering from moderate to severe MDD, with a focus on generating essential late-stage data that could reshape treatment standards. The clinical trial will assess two doses of CYB003 in a randomized, double-blind manner, evaluating changes in depressive symptoms using established measurement scales. This follows the initial Phase 3 trial, APPROACH, demonstrating Cybin’s dedication to thorough scientific exploration in mental health.

The growing acceptance of innovative therapies is underscored by industry experts, validating the necessity for alternative approaches to mental health treatment, thus enhancing Cybin’s influence within this dynamic sector. The company remains committed to transforming mental healthcare through groundbreaking developments better suited to meet the needs of those affected by these challenging conditions.

Related news for (CYBN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.